Featured speaker and receiving an honorary Doctor of Engineering at the University of New Haven Spring 2016 Commencement Ceremony
Ming Hsieh is the chief executive officer and founder of Fulgent Diagnostics, a California-based leader in the development of flexible and affordable genetic testing. The company, which he launched in 2011, focuses on cancer drug research, personalized cancer treatments and genetic diagnostics.
Prior to forming Fulgent, Hsieh was the founder and CEO of Cogent, Inc., a software company that revolutionized automated fingerprint identification. Under his leadership, Cogent became the worldwide leader of biometric identification services and products. The company, which went public in 2004, provides the technology used by the U.S. Department of Homeland Security for real-time identification to expedite the entry/exit process for travelers around the world who are entering the U.S. In 2010, Cogent was acquired by 3M, a Fortune 100 company.
A self-made entrepreneur from China, Hsieh came to the United States in 1980 after two years of college at the South China Institute of Technology, now known as the South China University of Technology. He enrolled at the University of Southern California and earned both a bachelor’s degree and a master’s degree in electrical engineering.
In 1985, Hsieh founded AMAX Information Technologies, a computer server and storage systems company. Prior to that, he served as a research and development engineer at International Rectifier.
Hsieh currently serves as a board member of Fortinet, a developer of secure cyber security solutions, and is a trustee at the University of Southern California and at Fudan University. In 2015, he was elected to the National Academy of Engineering, one of the highest professional honors awarded to an engineer.
The Ming Hsieh Department of Electrical Engineering at the University of Southern California, the oldest and largest department in the university’s Viterbi School of Engineering, is named in his honor. In 2010, he established USC’s Ming Hsieh Institute for Engineering Medicine for Cancer, which supports research at the intersection of engineering, medicine and science in the quest to cure cancer.